Kailera Therapeutics, Inc. (KLRA)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $2.32B
- P/E ratio
- —
- EPS
- —
- Volume
- 380,770
- 52-week high
- —
- 52-week low
- —
- Open
- $18.74
- Day high
- $18.98
- Day low
- $17.87
Financial highlights
Annual financials for Kailera Therapeutics, Inc. are being compiled and will appear here soon.
About Kailera Therapeutics, Inc.
Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.
- CEO
- Ronald C. Renaud Jr.
- Employees
- 145
- Country
- US
- IPO date
- Apr 17, 2026
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Kailera Therapeutics, Inc.'s stock price today?
- KLRA is trading at $17.91 as of Jul 20, 2026.
- What is Kailera Therapeutics, Inc.'s market cap?
- Kailera Therapeutics, Inc. (KLRA) has a market capitalization of $2.32B.
- What sector is Kailera Therapeutics, Inc. in?
- Kailera Therapeutics, Inc. operates in the Healthcare sector.